Hôpital Tenon

corporate_fareorganization

Hôpital Tenon

- Funding / Projects
  (45)

45 Projects, page 1 of 9

Title of the study: ESTROTEPREDIC - PET/CT with 16a-[18F]-Fluoro-œstradiol: an in vivo biomarker for predicting response to hormone treatment of metastatic breast cancer?
assignment_turned_inProjectPartners:Hôpital Tenon
Hôpital Tenon
Funder: Institut National du Cancer Project Code: INCa-DGOS-3941
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Impact des facteurs génétiques et de biomarqueurs urinaires dans la stratégie de diagnostic précoce des cancers de la prostate agressifs.
assignment_turned_inProjectPartners:Hôpital Tenon
Hôpital Tenon
Funder: Institut National du Cancer Project Code: INCa-DGOS-1093
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
BIG-RENAPE: Clinical and biological Digestive Peritoneal Carcinomatosis data base from the French National Network of Peritoneal Surface Malignancies (RENAPE)
assignment_turned_inProject2014 - 2017Partners:HCL, CHUG, Institut Gustave Roussy, Institut Bergonié, ICM-VAL D'AURELLE +24 partners
HCL,
CHUG,
Institut Gustave Roussy,
Institut Bergonié,
ICM-VAL D'AURELLE,
Centre Hospitalier Universitaire de Toulouse,
Hôpital Tenon,
Hôpital Louis Mourier,
HUS,
Institut Claudius Regaud,
Centre Hospitalier Universitaire de Limoges,
Hôpital Hôtel-Dieu,
Institut de Cancérologie de Lorraine,
Centre Hospitalier Universitaire de La Réunion,
Centre François Baclesse,
CHU Marseille - Hôpital la Timone,
Hôpital Claude Huriez,
Centre hospitalier universitaire de Poitie,
Centre Léon Bérard,
Groupe Hospitalier Diaconesses Croix Saint Simon,
Groupe Hospitalier Lariboisière - Fernand Widal,
Centre Hospitalier Universitaire de Saint-Étienne,
Institut Curie,
Centre Hospitalier Universitaire de Reims,
Hôpital le Bocage,
Institut Paoli-Calmettes- (IPC),
Hôpital de l'Archet,
CHUAP,
Institut de Cancérologie de l'Ouest
Funder: Institut National du Cancer Project Code: INCa-7415
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Use of bisphosphonates and risk of cancer incidence in the E3N cohort
assignment_turned_inProject2013 - 2015Partners:Hôpital Tenon, INSERM U1018- CESP
Hôpital Tenon,
INSERM U1018- CESP
Funder: Institut National du Cancer Project Code: INCa-6953
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.
assignment_turned_inProjectPartners:HCL, Hôpital de la Croix-Rousse, Hôpital Beaujon, Hôpital Saint-Antoine, Hôpital Purpan +25 partners
HCL,
Hôpital de la Croix-Rousse,
Hôpital Beaujon,
Hôpital Saint-Antoine,
Hôpital Purpan,
Université de Lille III (Charles-de-Gaulle),
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Hôpital Louis Mourier,
CHU Marseille - Hôpital la Timone,
Centre Hospitalier Universitaire de Nîmes,
Hôpital Tenon,
Centre Hospitalier Universitaire de Rennes,
HUS,
Hôpital Trousseau,
Hôpital Édouard Herriot,
Centre Hospitalier Universitaire d'Angers,
Hôpital Avicenne,
Centre Georges-François Leclerc,
Centre Léon Bérard,
Hôpital Ambroise Paré,
Institut Paoli-Calmettes- (IPC),
Institut Gustave Roussy,
Hôpital Européen Georges Pompidou (HEGP) - AP-,
Hôpital le Bocage,
Hôpital Claude Huriez,
Hôpital Charles-Nicolle,
Groupe Hospitalier Lariboisière - Fernand Widal,
Hôpital Hôtel-Dieu,
Hôpital Robert Debré,
Hôpital Haut-Lévêque
Funder: Institut National du Cancer Project Code: INCa-DGOS-3768
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

Hôpital Tenon

Hôpital Tenon

45 Projects, page 1 of 9

Title of the study: ESTROTEPREDIC - PET/CT with 16a-[18F]-Fluoro-œstradiol: an in vivo biomarker for predicting response to hormone treatment of metastatic breast cancer?

Impact des facteurs génétiques et de biomarqueurs urinaires dans la stratégie de diagnostic précoce des cancers de la prostate agressifs.

BIG-RENAPE: Clinical and biological Digestive Peritoneal Carcinomatosis data base from the French National Network of Peritoneal Surface Malignancies (RENAPE)

Use of bisphosphonates and risk of cancer incidence in the E3N cohort

Phase II/III randomised multicentre trial using a factorial design evaluating the advantage (i) of a strategy of primary surgery vs primary chemotherapy and (ii) chemotherapy with XELOX vs ECF in resectable gastric signet ring cell adenocarcinomas.

Loading